Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here


Celebrating Failure in a Tough Drug Industry; As Few as 1 Out of 10,000 Compounds Tested Get FDA Approval

New York, NY, March 9, 2017 — Jonathan D. Rockoff reports in The Wall Street Journal after making the difficult decision to scrap a once-promising drug program, the biotech firm Ironwood Pharmaceuticals in Cambridge, Mass., did something unusual: It gathered to celebrate.

With dozens of staffers in attendance, the “drug wake” at Ironwood featured seven-layer dip, homemade cupcakes and a bittersweet send-off.

“It’s hard to say goodbye, so I won’t,” said Mark Charest, who works on regulatory affairs at the company.  “I’ll say, ‘Thank you—thank you to the peptide.’” Continue reading

R&D Council of New Jersey Accepting 2017 Edison Patent Award Submission Until May 26

Chatham, NJ, February 17, 2017 ― The Research & Development Council of New Jersey is now accepting, until May 26, submissions for its 2017 Edison Patent Awards.

To learn more or to apply for the 2017 Edison Patent Awards, click here.

Winners will be honored at the annual Edison Patent Awards Ceremony & Reception on November 2. Continue reading

Princeton University and Benefunder Agreement Offers Opportunities to Support Research

Princeton, NJ, February 14, 2017 — Princeton University has entered into an agreement with Benefunder to offer the opportunity for donors to support Princeton’s faculty engaged in leading-edge research and innovation programs through Benefunder’s philanthropic “marketplace.”

Benefunder provides a targeted approach for donors who want to focus their support on research and innovation that addresses causes about which they feel most passionate. Continue reading

Princeton, Rowan and Rutgers-Camden Ranked High for Academic R&D Expenditures in the Life Sciences for Region

Glassboro, NJ, February 13, 2017 — The Greater Philadelphia Region Life Sciences Report ranks Rowan University seventh among 19 colleges and universities in the region in R&D expenditures related to life sciences, third among the public institutions.

Princeton University and Rutgers-Camden also were included on the list, which is published on page 30 of the report.

The ranking is based on 2014 figures from the National Science Foundation and includes funds spent on biological sciences, chemical engineering, chemistry, medical sciences and other life sciences. Continue reading

Bloomberg Index: New Jersey 4th Most Innovative State; Massachusetts Is No. 1 Followed by California

New Jersey pin horizontalNew York, NY, January 24, 2017 — According to the latest Bloomberg Index published in December 2016, New Jersey is the fourth most innovative state in the country.

Massachusetts, fueled by its higher-education institutions and an unemployment rate that is almost two points below the national average, was once again recognized as the top state for innovation with a total score of 94.82.

California and Washington followed Massachusetts in the rankings. Continue reading

PhRMA: Three Things to Know About 2016 Drug Approvals

phrma-logo-whiteWashington, DC, January 10, 2017 — PhRMA Director of Public Affairs Andrew Powaleny writes In 2016, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 22 new medicines to treat a broad range of illnesses for patients in need.

These much-needed new treatments include medicines for multiple sclerosis, chronic lymphocytic leukemia, ovarian and bladder cancer and the very rare spinal muscular atrophy (SMA).

Among these new medicines, more than a third are treatments for rare diseases and more than one-third are first-in-class, meaning they use a new, unique approach to treating an illness that has never before been available. Continue reading

Reuters: FDA’s New Drug Approvals in 2016 Fall to Six-Year Low

FDA approvedWashington, DC, January 4, 2017 — Reuters reports that 2016 was a disappointing year for new drug approvals with the U.S. Food and Drug Administration (FDA) clearing just 22 new medicines for sale, the lowest number since 2010 and sharply down on 2015’s tally of 45.

Across the Atlantic, the European Medicines Agency recommended 81 new prescription products against a 2015 total of 93.  Unlike the FDA, the EMA includes generic drugs in its list.

The slowdown suggests the pharmaceuticals industry may be returning to more normal productivity levels after a spike in approvals in 2014 and 2015, when the haul of new drugs reaching the market hit a 19-year high. Continue reading

SSTI: 50 State Table Reveals University R&D Change Over Five Years

R&D 5Westerville, OH, December 19, 2016 ― Robert Ksiazkiewicz reports in the State Science & Technology Institute (SSTI) news blog that nearly half of the U.S. states and the District of Columbia saw a 10 percent or greater increase in higher education R&D expenditures from FY 2010 to FY 2015.

Five of those states — Connecticut, Georgia, Massachusetts, Nebraska, and Utah — saw at least a 20 percent change, according to the National Science Foundation’s (NSF) Higher Education Research and Development (HERD) survey for 2015.

Between FY10-15 overall U.S. research and development (R&D) spending at U.S. universities grew 12.1 percent, from about $61.2 billion to $68.7 billion. Continue reading

Celebrating 250th Anniversary, Rutgers Office of Research and Economic Development Publishes 2016 Report

rutgers-2016-ored-annual-reportNew Brunswick, NJ, December 16, 2016Rutgers University’s Office of Research and Economic Development (ORED) has published its 2016 annual report, reflecting the work it has done as the university has celebrated its 250th Anniversary this year.

In his introductory letter, Christopher J. Molloy, Ph.D., R.Ph., Senior Vice President for Research and Economic Development, said “Rutgers’ long and proud history was shaped by a series of pioneers, some of whom are profiled in the 250th celebration series on ‘Revolutionary Thinkers.’  Among them are Nobel-Prize winner Selman Waksman, actor and athlete Paul Robeson, Nobel Prize-winning economist Milton Friedman, and Justice Ruth Bader Ginsburg.”

“The university’s history has included numerous major transitions, such as Congress conferring land-grant status in 1864 and Rutgers admitting the first women students in 1918,” Molloy continued. Continue reading

PhRMA Report Highlights More Than 250 Vaccines in Development

Vaccine kidWashington, DC, December 11, 2016 — Hannah Mooney writes on the Pharmaceutical Research and Manufacturers of America’s (PhRMA) blog, The Catalyst, that, more than 200 years ago, the first vaccine was developed for smallpox, and now, the disease has been eradicated worldwide.

In addition, in the United States, the transmission of poliovirus, measles and rubella have been eliminated.  These are examples of tremendous scientific progress, and through our growing understanding of how these and other diseases work at the molecular level, many new therapeutic and preventative vaccines have been developed.

A new PhRMA report, “Medicines in Development for Vaccines,” offers insight into the more than 250 vaccines currently in development, designed to prevent and treat illness. Continue reading